A clinical trial assessing Alpha1H for treatment of Non-Muscle Invasive Bladder Cancer
Latest Information Update: 06 Jul 2023
At a glance
- Drugs Alpha lactalbumin oleic acid (Primary)
- Indications Bladder cancer
- Focus Therapeutic Use
Most Recent Events
- 06 Jul 2023 New trial record
- 01 Jul 2023 According to Hamlet Pharma AB media release, the U.S. Food and Drug Administration (FDA) has cleared its Investigational New Drug (IND) application for Alpha1H, a highly selective synthetic peptide for treatment of non-muscle invasive bladder cancer (NMIBC). Working closely with their US based partner, Target Health LLC, a New Jersey-based, full-service CRO, the FDAs Study May Proceed letter begins a hopeful new chapter for the treatment of NMIBC patients globally